Pradeep K Sheokand, Denis Lacabanne, Andrew M James, Stefania Della Vecchia, Jonathan J Ruprecht, Joris van der Kleij, Keira Turner, Jessica Müller-Niva, Miia H Salo, Benjamin Jenkins, Susannah K Leese, Nidhi Juneja, Chak Shun Yu, Clarissa D Booth, Martin S King, Johanna Uusimaa, Jill M Weimer, Albert Koulman, Reetta Hinttala, Filippo M Santorelli, Maria Marchese, Michael P Murphy, Edmund R S Kunji, Kasparas Petkevicius
Loss-of-function mutations in the endoplasmic reticulum membrane protein CLN8 cause Batten disease, a neurodegenerative lysosomal storage disorder. CLN8 acts with the lysosomal enzyme CLN5 to produce bis(monoacylglycero)phosphate (BMP), a signature lysosomal phospholipid with unique S,S stereochemistry. However, the role of CLN8 in this pathway has remained unclear. Here we establish that CLN8 is a glycerophosphoglycerol acyltransferase that catalyses the stereospecific acylation of S,S-glycerophosphoglycerol to generate S,S-lysophosphatidylglycerol, the CLN5 substrate in BMP synthesis. Cryo-electron microscopy structures define the CLN8 active site and support a ping-pong acyl transfer mechanism. Batten disease mutations impair CLN8 enzymatic activity and abolish BMP production in mice. Exogenous S,S-lysophosphatidylglycerol, but not the R,S stereoisomer, restores BMP synthesis in CLN8-deficient cells and mice and improves neurological phenotypes in cln8 mutant zebrafish. These findings define the function of CLN8, explain the biochemical basis of CLN8 Batten disease and establish BMP precursor supplementation as a proof-of-concept therapeutic strategy.